News

Previously at ev3, Dr Spaargaren was vice president of international clinical affairs since 2002, where he was responsible for driving new product development from R&D to acceptance by

Under the terms of the agreement, OncoGenex is entitled to receive royalty payments from future Tocosol Paclitaxel sales and a percentage of sub-licensing royalty and milestone payments received

Receipt of $15 million was triggered by acceptance of the Remoxy new drug application by the FDA. Receipt of an additional $5 million was triggered by FDA’s acceptance

The priority review status provides for a review period of six months from the date of submission. The Embeda capsule new drug application was submitted on June 30,

Under the terms of the agreement, the payment was triggered by the initiation of a Phase I clinical study by Novartis of QAX935. QAX935 is a novel agonist

Oncothyreon expects to begin marketing the offering in the second week of September, 2008. The per share offering price to the public will be determined based on market

In connection with the agreement, Purdue has agreed to grant Mallinckrodt a royalty-bearing license to sell limited quantities of generic versions of 10mg, 20mg, 40mg, and 80mg extended-release

Study 301 is a multinational, randomized, placebo-controlled, induction-design Phase III trial evaluating up to 118 patients. The trial is approximately four weeks in duration and includes an initial

This multi-center, double-blind, randomized and placebo-controlled clinical trial compares the safety and efficacy of Prulifloxacin versus placebo in adult travelers suffering from acute bacterial gastroenteritis. Clinical trial sites